The aim of the present study was to assess galcanezumab efficacy–a monoclonal antibody that targets the CGRP molecule–in reducing standard variables of outcome (headache/migraine days, pain intensity, analgesics consumption, and migraine-related disability) and ictal photophobia. This evidence concerns the gene CALCA and Photophobia.